Upstream
Affordable Breakthrough: Revolutionizing Monoclonal Antibodies
🔬 Recent innovations in cell culture media make monoclonal antibody development more affordable, revolutionizing biological therapeutics. 💉👩🔬
The Game-Changing Future of Cell and Gene Therapy Relies on Recombinant Albumin
🔬 Stay updated on the future of cell and gene therapy with reliable and affordable recombinant albumin. 🚀 CellTherapy GeneTherapy
Unmatched Productivity and Seamless Scalability: Advantages of the XCell® ATF System for Upstream Process Intensification
📌 The XCell® ATF system offers unmatched productivity and seamless scalability for upstream process intensification. 📌 This system is advantageous for bioprocessing upstream, including culturing of animal or microbial cells. 📌 The system uses controlled feeding, aerating, and process strategies in different vessel types. 📌 It also provides options for assays, bioreactors, cell culture media, and expression platforms, among others. 📌 Downstream processing involves removing contaminants through centrifugation, filtration, and chromatographic technologies. 📌 The XCell® ATF system offers advantages in downstream processing, such as filtration, separation/purification, and viral clearance. 📌 The system is also beneficial for manufacturing drug products, including biosimilars and cell/gene therapies. 📌 Analytical technologies are used to characterize biological products, manufacturing processes, and raw materials. 📌 The XCell® ATF system supports analytical applications for culture development, cell line development, and product characterization. 📌 The system is advantageous for businesses in the biopharmaceutical industry, providing support for careers, economics, and regulatory affairs. ⚡️ In summary, the XCell® ATF system offers productivity and scalability benefits for bioprocessing, including upstream and downstream processing, manufacturing, analytical applications, and business support.
Bluebird bio receives US FDA nod for sickle cell therapy
📢 Bluebird bio has received approval from the US FDA for its sickle cell therapy. 💉 This therapy, called LentiGlobin, is a gene therapy that aims to treat sickle cell disease. 🩸 Sickle cell disease is a genetic condition that affects the shape and function of red blood cells. 👨⚕️ The treatment involves modifying the patient's own stem cells to produce healthy red blood cells. 🗓️ The approval is based on positive results from clinical trials showing efficacy and safety. 🌍 This therapy offers hope for patients with sickle cell disease, who currently have limited treatment options.
